Background. Physiological hyperinsulinemia in lean human subjects stimulates sympathetic nerve activity and blood flow in skeletal muscle, but the underlying mechanism is unknown. Potential mechanisms include central neural or peripheral actions of insulin. Glucocorticoids may potentially interfere with both such actions and thereby may attenuate sympathoexcitatory and vasodilatory effects of insulin in skeletal muscle.
Methods and Results. To determine whether insulin-induced sympathetic activation and vasodilation are attenuated by dexamethasone, we measured muscle sympathetic nerve activity and muscle blood flow during euglycemic hyperinsulinemia before and after short-term administration of this pharmacological agent. Insulin concentrations, which normally doubled sympathetic activity and markedly increased blood flow, had no such stimulatory effect after short-term dexamethasone administration. In contrast, responses to two noninsulin sympathetic stimuli, the Valsalva maneuver and immersion of the hand in ice water, and the vasodilatory response to calf vascular occlusion were not altered by dexamethasone.
Conclusions. These results demonstrate a dramatic impairment of insulin-induced sympathetic activation and vasodilation by dexamethasone in lean, healthy humans. This study suggests that dexamethasone administration to lean subjects may offer an experimental model to examine underlying mechanisms that regulate the interplay between cardiovascular, sympathetic, and metabolic effects of insulin. (Circulation 1993; 88:388-394) KEY WORDs * sympathetic nervous system * microneurography * neuropeptide Y * corticotropin releasing hormone
Insulin not only plays an important role in the regulation of intermediary metabolism but also has effects on the cardiovascular system.1-7 There is increasing evidence that in lean, healthy humans, acute elevation of insulin to high physiological concentrations stimulates both sympathetic activity8-13 and blood flow10 '11"4'15 (Table) .
In contrast, insulin infusion at the same rate, performed after 48 hours of dexamethasone administration, had no detectable effect on MSNA, calf blood flow, or calf vascular resistance, even though increases in insulinemia were comparable (Fig 1 and Table) . Indeed, at the end of the second hour of infusion, plasma insulin concentrations tended to be higher (625 ±99 versus 411±41 pmol/L, P=.09) than those observed during the control experiments because glucose was infused at the same rate as during the control studies and led to hyperglycemia (8.2±0.2 mmol/L), which in turn stimulated endogenous insulin production. As for MSNA, insulin infusion after dexamethasone administration also did not have any detectable effect on plasma noradrenaline concentrations.
During both protocols, blood pressure remained unchanged. Heart rate increased significantly (P<.05) by 7±2 beats per minute when insulin was infused alone but did not change significantly when insulin was infused after dexamethasone administration (Table) .
In protocol 1 Unlike insulin infusion, which had no effect on MSNA after dexamethasone administration, noninsulin stimuli to sympathetic outflow evoked comparably large increases in MSNA before and after dexamethasone administration. Peak study, during the first hour of insulin/glucose infusion, stimulation of MSNA and blood flow was completely abolished by dexamethasone even though glucose uptake was only partially decreased. Third, and most important, during the second hour of infusion, glucose uptake increased similarly as it did during the first hour of the studies performed without dexamethasone administration but was not associated with any significant increase in MSNA and calf blood flow. Conversely, in the absence of dexamethasone administration, insulin/glucose infusion at the rate used in the present experiments consistently has been found to evoke robust increases in MSNA and muscle blood flow within 60 minutes of the start of infusion.10,11,15 Thus, whereas the present findings suggest that it is unlikely that suppression of insulin-induced stimulation of MSNA and calf blood flow by dexamethasone is related to differences in glucose uptake alone, we cannot exclude the possibility that this agent may have altered a carbohydrate metabolism-related signal, which may trigger stimulation of muscle blood flow and sympathetic activity during euglycemic hyperinsulinemia. An alternative peripheral mechanism is that dexamethasone may have inhibited insulin-induced vasodilation in skeletal muscle. Such vasodilation, for example, could be related to a direct vasodilator effect of insulin, as suggested by the observation of dose-dependent increases in forearm blood flow during local intra-arterial insulin infusion into human forearm tissue. a113 compared effects of systemic versus local hyperinsulinemia on MSNA as determined by measurements of local norepinephrine spillover. They showed that insulin/ glucose infusion at the rate used in the present studies is a potent stimulus to MSNA. In contrast, local hyperinsulinemia had no detectable sympathoexcitatory effects in these human subjects. Similarly, even though this issue is more controversial,33 several studies examining the effects of local intra-arterial insulin infusion on muscle blood flow found no vasodilatory effects,3940 whereas in the present and other studies,10'11,15,41 systemic hyperinsulinemia consistently has been found to evoke large increases in muscle blood flow.
An important unresolved issue is whether, during euglycemic hyperinsulinemia, sympathetic activation and vasodilation in skeletal muscle are causally related. Although the present findings showing that dexamethasone abolishes both insulin-induced stimulation of MSNA and blood flow are consistent with such a concept, they do not show this conclusively. In humans, an earlier study suggested that insulin-induced stimulation of muscle blood flow may be sympathetically mediated because propranolol infusion attenuated forearm vasodilation evoked by intra-arterial insulin infusion. 33 However, in this study, intra-arterial insulin infusion without concomitant glucose administration resulted in hypoglycemia and epinephrine release, which in turn may have caused 8-adrenergically mediated vasodilation. Indeed, recent findings suggest that during euglycemic hyperinsulinemia, a situation in which epinephrine does not increase, propranolol infusion does not significantly attenuate stimulation of calf blood flow. 41 Potential neural sympathetic vasodilator mechanisms that may mediate stimulation of calf blood flow during euglycemic hyperinsulinemia include cholinergic vasodilation42'43 and nonadrenergic-noncholinergic vasodilation. 44 In this regard, preliminary findings from this laboratory suggest that stimulation of muscle blood flow during euglycemic hyperinsulinemia may not be mediated primarily by cholinergic mechanisms. 41 Plethysmographic measurements of calf blood flow are a composite of both muscle and skin blood flow. However, it is unlikely that our results have been markedly influenced by changes in skin blood flow, since recent findings indicate that skin blood flow does not change during euglycemic hyperinsulinemia in humans. 45 These data for skin blood flow are consistent with neurophysiological data demonstrating that, in contrast to MSNA, skin sympathetic nerve activity also does not change during hyperinsulinemia in humans.9 '12 Dexamethasone administration in the present studies also attenuated the increase in heart rate evoked by euglycemic hyperinsulinemia. Such stimulation of heart rate has been thought to indicate cardiac sympathetic activation because it is abolished by propranolol administration.46 Thus, the present findings are consistent with the interpretation that dexamethasone may also attenuate cardiac sympathetic activation.
In summary, these findings indicate that in lean, healthy humans, dexamethasone administration dramatically impairs the ability of insulin to stimulate sympathetic activity and blood flow in skeletal muscle. Elucidating the exact underlying mechanism by which dexamethasone exerts its effects may be of potential importance, because recent evidence in humans suggests that impaired ability of insulin to stimulate muscle blood flow could contribute to insulin resistance. 15 Thus, dexamethasone administration to lean subjects may offer an experimental model to study underlying mechanisms that regulate the interplay between cardiovascular, sympathetic, and metabolic effects of insulin.
